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Both general and regional anaesthe-
sia are associated with a high rate of 
sympathicolysis-induced hypoten-
sion that requires fast-acting and re-
liable anti-hypotonic agents to stabi-
lise blood pressure. For decades hy-
potension was avoided by the provi-
sion of excessive fluid preload, how-
ever, this practice faces increasing 
criticism [3]. In Germany, cafedrine/
theodrenaline (Akrinor®) is approved 
as an anti-hypotensive agent along-
side a few other agents.
Background
Cafedrine/theodrenaline was introduced 
in Germany in 1963, and pre-clinical da- 
ta showed a beta-adrenergic and an alpha-
adrenergic component [22, 25, 26]. The net 
effect is beta-adrenergic [25]. The combi-
nation preparation increases mean arte- 
rial pressure (MAP), cardiac stroke vol-
ume and cardiac output [18, 25]. Com-
pared to alpha-adrenergic sympathomi-
metic agents, cafedrine/theodrenaline was 
shown to cause less deterioration of renal, 
cerebral and coronary perfusion [5]. In ad-
dition, clinical practice with alpha-adren-
ergic sympathomimetic agents requires 
measures to control refectory critical bra-
dycardia, for example with atropine [7]. A 
study in dogs demonstrated that increased 
myocardial oxygen consumption caused 
by positive inotropic cafedrine/theodren- 
aline effects are compensated for by en-
hanced coronary perfusion, increasing the 
myocardial oxygen supply [9]. The phar-
macologic properties of this drug combi-
nation may explain the distinctly favour-
able effects in patients with chronic isch-
aemic heart disease [11, 15]. In addition, 
cafedrine/theodrenaline combination 
seems to offer benefits from a metabolic 
standpoint because of the lower lipolytic 
effect compared with catecholamines, par-
ticularly under hypoxic conditions in acute 
myocardial infarction or shock [21].
Although cafedrine/theodrenaline is 
widely accepted in the management of hy-
potensive states in anaesthesia, intensive 
care and emergency medicine [1, 6, 16], 
few pharmacodynamic data have been 
published [13], and it is therefore impor-
tant to collect data under routine clinical 
practice conditions. Cafedrine/theodren-
aline is routinely administered at our in-
stitution to patients in whom a quick and 
sustained MAP increase for 15–20 min is 
warranted and feasible with a single drug 
administration and without the vasopres-
sor side effect of bradycardia; during these 
15–20 min, fluid volume can be balanced. 
Gender-related differences in the ED50 of 
cafedrine/theodrenaline have previously 
been reported by our group [13]. To con-
firm and expand on this observation un-
der routine anaesthesia conditions, the 
time to 10 % increase in MAP after ad-
ministration of cafedrine/theodrenaline 
was examined. We hypothesized that gen-
der, heart failure and use of beta-blockers 
influence the effectiveness of cafedrine/
theodrenaline.
Methods
This study was approved by the Institu-
tional Review Board at the University 
Hospital Carl Gustav Carus Medical Fac-
ulty, Fetscherstrasse 74, Dresden, Germa-
ny (EK255122004, 17.01.2005). The re-
cords from 353 consecutive anaesthe-
sia patients at our institution who re-
ceived cafedrine/theodrenaline were col-
lected and retrospectively evaluated. Pa-
tients were included in the study between 
July and November 2007, irrespective of 
the type of surgery, and received cafe-
drine/theodrenaline to manage hypoten-
sion during anaesthesia. To reflect a re-
al-life cross-section of patients in a Ger-
man hospital, patients from the following 
departments were included: orthopae-
dics, trauma surgery, neurosurgery, vis-
ceral- thoracic and vascular surgery, gyn-
aecology, urology, oral and facial surgery 
and eye surgery.
All patients fasted 2 h prior to induc-
tion and received 7.5 mg midazolam OD 
(Dormicum, Roche, Grenzach-Wyhlen, 
Germany) 45 min prior to arrival in the 
operating theatre. Concomitant medica-
tion, including anti-hypertensives such as 
beta-blockers, was continued as indicat-
ed by the standard operating procedures 
of the department. A 5-lead electrocardio-
gram, including measurement of segmen-
tal ST depression (II, aVF, V5), and pulse 
oximetry was recorded. Non-invasive os-
cillometric blood pressure was monitored 
in 5 min intervals on the right upper arm 
(IntelliVue, MP70, Philips, Böblingen, 
Germany). Values were manually trans-
ferred to anaesthesia protocols. The fol-
lowing data were recorded: age, gender, 
height, body weight, current beta-blocker 
therapy, American Society of Anesthesiol-
ogists physical status and individual dosage 
of cafedrine/theodrenaline per injection.
A.R. Heller · J. Heger · M. Gama de Abreu · M.P. Müller
Department of Anaesthesia and Intensive Care Medicine, Department of Anesthesiology and Critical Care 
Medicine, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
Cafedrine/theodrenaline 
in anaesthesia







Published online: 11 March 2015
© The Author(s) 2015. This article is published 
with open access at Springerlink.com
190 | Der Anaesthesist 3 · 2015
Originalien
General anaesthesia was induced with 
1.5 mg/kg propofol (Propofol 1 %, Fre-
senius-Kabi, Bad Homburg, Germany) 
and 0.5 µg/kg sufentanil (Sufenta Jans-
sen-Cilag, Neuss, Germany). Tracheal in-
tubation was facilitated by 0.5 mg/kg ro-
curonium (Esmeron, Organon, Ober-
schleißheim, Germany). General anaes-
thesia was maintained with desflurane 
(Suprane, Baxter, Unterschleißheim, 
Germany) in O2/N2O (35 %/60 %). Pa-
tients were mechanically ventilated with 
a minute volume adequate to maintain 
end-tidal pCO2 of 36–40 mmHg at a fresh 
gas flow of 1 l/min (Primus, Dräger, Lü- 
beck, Germany). Neuraxial anaesthesia 
(spinal anaesthesia, epidural anaesthesia) 
was performed with approved local an- 
aesthetics in awake seated patients [19].
In patients with ≥ 5 % drop in MAP 
cafedrine/theodrenaline was adminis-
tered to maintain MAP within a 20 % 
drop from baseline. We chose the 5 % 
drop in MAP as the inclusion criterion 
to raise awareness that hypotension even 
in this range may be associated with late 
complications. Timing and doses were re-
corded in anaesthesia protocols. The ob-
servation period in this study was limited 
to 30 min after the drop in MAP because 
the variability of factors affecting MAP, 
such as additional volume therapy, ongo-
ing blood loss and the use of other drugs 
increases with time. Individual dosage 
was defined in accordance with a previous 
dose-finding study, in which the ED50 of 
cafedrine to achieve a 10 % MAP increase 
within 10 min was 0.53 mg/kg [13].
Administration of cafedrine/
theodrenaline
An ampoule of 2 ml cafedrine/theodren-
aline (Akrinor, AWD.pharma GmbH 
& Co. KG, Dresden, Germany) contains 
200 mg cafedrinhydrochloride, 10 mg 
theodrenalinehydrochloride, 0.4 mg sodi-
umdisulfite, ethanol 96 %, glycerol 85 %, 
sodium acetate 3 H2O, acetic acid 99 % 
and water. To enable fairly precise dos-
ing, 2 ml of cafedrine/theodrenaline were 
diluted in 8 ml of saline to a total of 10 ml, 
as suggested in the prescribing informa-
tion. Throughout the manuscript doses 
are given for the cafedrine component of 
the mixture. Due to the fixed milligram 
ratio of 1:20, the dosage of theodrenaline 
can be calculated by dividing the respec-
tive cafedrine dose by 20.
Endpoints
The primary endpoint was time to 10 % 
increase in MAP after administration of 
cafedrine/theodrenaline. Other study 
endpoints were stability of heart frequen-
cy and time to onset of effect dose rela-
tive to gender, beta-blocking agents and 
the presence of heart failure (NYHA ≥ 1).
Statistical analysis
Mean arterial blood pressure was calcu-
lated as MAP = diastolic + (systolic-dia-
stolic)/3. All data were anonymised and 




















Fig. 1 8 Effects of cafedrine/theodrenaline on mean arterial pressure (MAP, mean ± SE) injected at 
time point 0 (reference value) in male and female patients. Both MAP drop and increase were statis-
tically significant (p < 0.001, paired t-test), as was the between-group comparison with general linear 

























Fig. 2 8 Effects of cafedrine/theodrenaline on heart rate (mean ± SE) injected at time point 0 (ref-
erence value) in male and female patients. The difference between genders was not significant 
(p = 0.668), while the heart rate difference over time was statistically significant (p < 0.001)
 
analysed using the Statistical Package for 
Social Sciences for Windows, version 17.0 
(SPSS, Inc., Chicago, IL, USA). The pri-
mary study hypothesis was tested using a 
Kaplan–Meier analysis followed by a log-
rank test. General linear model statistics 
according to a two-way analysis of vari-
ance were applied for repeated measure-
ment analyses, followed by Sidak alpha 
adjustment for multiple comparisons. A 
paired t-test served for analysing point to 
point changes in haemodynamics. To en-
sure equal distribution of risk factors be-
tween the observed cohorts, categorical 
variables were compared with χ2 statistics.
Data are expressed as mean ± SD. To 
support readability and interpretation in 
. Figs. 1 and 2, data are presented as mean 
± SE. A p-value of < 0.05 was considered 
statistically significant.
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Cafedrine/theodrenaline in anaesthesia. Influencing factors in restoring arterial blood pressure
Abstract
Background. Hypotensive states that re-
quire fast stabilisation of blood pressure can 
occur during anaesthesia. In 1963, the 20:1 
mixture of cafedrine/theodrenaline (Akri-
nor®) was introduced in Germany for use in 
anaesthesia and emergency medicine in the 
first-line management of hypotensive states. 
Though on the market for many years, few 
pharmacodynamic data are available on this 
combination net beta-mimetic agent.
Aim. This study aimed to examine the drug 
combination in real-life clinical practice and 
recorded time to 10 % mean arterial blood 
pressure (MAP) increase and heart rate. Fur-
thermore, potential factors that influence 
drug effectiveness under anaesthesia were 
assessed.
Methods. Data were collected within a 
standardised anaesthesia protocol. A to-
tal of 353 consecutive patients (female/
male = 149/204) who received cafedrine/
theodrenaline after a drop in MAP ≥ 5 % were 
included in the study. The time to 10 % in-
crease in MAP, dosage of cafedrine/theodren-
aline, volume loading, blood pressure and 
heart rate were monitored over time.
Results. Patients were a mean (standard de-
viation) of 64.4 ± 15.1 years old with a base-
line MAP of 82 ± 14 mmHg, which dropped 
to a mean of 63 ± 10 mmHg during anaes-
thesia without gender differences. Cafedrine/
theodrenaline (1.27 ± 1.0 mg/kg; 64 ± 50 µg/
kg) significantly increased MAP (p < 0.001) by 
11 ± 16 mmHg within 5 min, reaching peak 
values within 17.4 ± 9.0 min. Heart rate was 
not affected in a clinically significant man-
ner. Cafedrine/theodrenaline induced a 10 % 
MAP increase after 7.2 ± 4.6 min (women) 
and after 8.6 ± 6.3 min (men) (p = 0.018). In-
dependent of gender, the dose of cafedrine/
theodrenaline required to achieve the ob-
served MAP increase of 14 ± 16 mmHg at 
15 min was significantly different in pa-
tients with heart failure [1.78 ± 1.67 mg/
kg (cafedrine)/89.0 ± 83.5 µg/kg (theodren-
aline)] compared with healthy patients 
[1.16 ± 0.77 mg/kg (cafedrine)/58.0 ± 38.5 µg/
kg (theodrenaline)] (p = 0.005). Concomitant 
medication with beta-blocking agents signif-
icantly prolonged the time to 10 % MAP in-
crease [9.0 ± 7.0 vs. 7.3 ± 4.3 min (p = 0.008)].
Conclusion. Cafedrine/theodrenaline quick-
ly restores MAP during anaesthesia. Female 
gender is associated with higher effective-
ness, while heart failure and beta-blocker ad-
ministration lower the anti-hypotonic effect. 
Prospective studies in defined patient popu-
lations are warranted to further characterise 
the effect of cafedrine/theodrenaline.
Keywords
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Cafedrin/Theodrenalin in der Anästhesie. Faktoren, die die Wirksamkeit 
bei der Wiederherstellung des Blutdrucks beeinflussen
Zusammenfassung
Hintergrund. Cafedrin/Theodrenalin (Akri-
nor®) wird in Deutschland für die Therapie 
von Blutdruckabfällen in Anästhesie und Not-
fallmedizin verwendet.
Ziel der Arbeit (Fragestellung). Die Studie 
untersucht potentielle Faktoren, die die Wirk-
samkeit des Arzneimittels beeinflussen.
Material und Methoden. Patientendaten 
wurden mittels Anästhesie-Protokollen ge-
sammelt. 353 Patienten (weiblich/männlich 
= 149/204), die Cafedrin/Theodrenalin nach 
einem Abfall des mittleren arteriellen Blut-
drucks (MAP) ≥ 5 % erhielten, wurden einbe-
zogen.
Ergebnisse. Die Patienten waren 64,4 ± 15,1 
Jahre alt und hatten einen Ausgangs-MAP 
von 82 ± 14 mmHg, der während der Anäs-
thesie unabhängig von Geschlecht auf einen 
Mittelwert von 63 ± 10 mmHg abfiel.
Cafedrin/Theodrenalin (1,27 ± 1,0 mg/
kg/64 ± 50 µg/kg) erhöhte den MAP inner-
halb von 5 min um 11 ± 16 mmHg (p < 0,001). 
Der maximale MAP war nach 17,4 ± 9,0 min 
erreicht; die Herzfrequenz wurde nicht 
im klinisch signifikanten Maß verändert. 
Cafedrin/Theodrenalin induzierte einen 
10 % MAP-Anstieg nach 7,2 ± 4,6 min bei 
Frauen und nach 8,6 ± 6,3 min bei Männern 
(p = 0,018). Unabhängig vom Geschlecht 
waren die Dosen von Cafedrin/Theodren-
alin, die zu dem beobachteten MAP-An-
stieg um 14 ± 16 mmHg nach 15 min füh-
rten, signifikant unterschiedlich zwisch-
en Patienten mit und ohne Herzinsuffizienz 
(1,78 ± 1,67 mg/kg (Cafedrin)/89,0 ± 83,5 µg/
kg (Theodrenalin) vs. 1,16 ± 0,77 mg/kg 
(Cafedrin)/58,0 ± 38,5 µg/kg (Theodrenalin), 
p = 0,005).
Gleichzeitige Medikation mit Betablock-
ern verlängerte die Zeit bis zum 10 % MAP-
Anstieg [9,0 ± 7,0 vs. 7,3 ± 4,3 min (p = 0,008)].
Schlussfolgerung. Theodrenalin/Cafe-
drin stellt den MAP nach Blutdruckabfällen 
schnell wieder her ohne die Herzfrequenz 
klinisch relevant zu verändern. Das Medika-
ment zeigt eine höhere Wirksamkeit bei Frau-
en, während Herzinsuffizienz und Betablo-
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Results
Data were collected for 353 consec-
utive anaesthesia patients (mean age 
64.4 ± 15.1) at a single institution who re-
ceived cafedrine/theodrenaline to treat 
hypotensive states during surgery be-
tween July and November 2007. Demo-
graphic characteristics, baseline values 
and treatment are presented in . Table 1. 
172 and 181 patients received general and 
neuraxial anaesthesia, respectively.
The MAP dropped from a mean base-
line value of 82 ± 14 to 63 ± 10 mmHg 
(equivalent to 78 ± 12 % of the baseline 
level; p < 0.001). MAP increase after 5 min 
was also statistically significant (p < 0.001), 
however mean baseline MAP values and 
the drop during surgery did not differ be-
tween genders (. Fig. 1, . Table 2). MAP 
increased by 11 ± 16 mmHg (p < 0.001) 
5 min after administration of cafedrine/
theodrenaline, while heart rates remained 
at a mean of 66 ± 18 bpm over 20 min. 
The highest MAP values were achieved 
17.4 ± 9.0 min after the drop and admin-
istration of 1.27 ± 1.0 mg cafedrine/kg, 
independent of gender. For ease of trans-
ferring applied cafedrine/theodrenaline 
dosages into the reader’s clinical practice, 
. Table 3 gives the relevant standard dos-
es, dilutions and relations to body weight. 
Heart rates before the drop in MAP were 
a mean of 71 ± 18 and 67 ± 19 bpm after 
the drop (p < 0.001).
Cafedrine/theodrenaline 
effectiveness according to gender
Heart rates did not differ significantly be-
tween genders (. Fig. 2). After the drop 
in blood pressure cafedrine/theodrena-
line induced a 10 % increase in MAP sig-
nificantly earlier in women 7.2 ± 4.6 vs. 
8.6 ± 6.3 min in men (p = 0.018) (. Table 2, 
. Fig. 3), however, the duration of the 
pressure-elevating effect as assessed by 
the time to peak MAP did not differ in a 
gender-related manner (. Table 2).
Cafedrine/theodrenaline in 
patients with heart failure
The time to highest MAP was lon-
ger for the 67 patients with heart fail-
ure than for patients without heart prob-
lems (p = 0.007) (. Fig. 4). In addition, 
the dose (mg/kg body weight) to achieve 
MAP increase in a similar range at 15 min 
(by 14 ± 16 mmHg in heart failure patients 
and by 14 ± 14 mmHg in healthy patients) 
were 1.78 ± 1.67 mg/kg in patients with 
heart failure and 1.16 ± 0.77 mg/kg in the 
healthy cohort (p = 0.005). This difference 
was independent of gender.
Cafedrine/theodrenaline in 
patients with beta-blocking agents
Concomitant medication with be-
ta-blocking agents significantly pro-
longed the time to 10 % increase in 
MAP (n = 111, 9.0 ± 7.0 vs. 7.3 ± 4.3 min, 
p = 0.008) (. Fig. 5). Factors potentially 
affecting the effectiveness of beta-stim-
ulants such as the extent of volume load 
(492 ± 288 ml without beta-blocking 
agents and 475 ± 289 ml with beta-block-
ing agents) prior to blood pressure drop 
did not differ between the groups.
Discussion
Risks of hypotonia 
during anaesthesia
Induction of anaesthesia induces sym-
pathicolysis, regardless of the type of an-
aesthesia, whether general or neuraxial, 
and poses a risk of hypotension, in par-
ticular when the administration of in-
travenous fluids is restricted [12, 17, 27]. 
The dilation of resistance and capacitance 
vessels in the blocked area, with a subse-
quent decrease of pressure in the system-
ic and pulmonary circulation, leads to a 
reduction in cardiac preload and after-
load, posing a risk of cerebral or myocar-
dial ischaemia as well as acute renal failure 
[10, 14]. The use of balanced anti-hypo-
tonic agents such as cafedrine/theodren-
aline may be beneficial when combined 
with gentle volume loading, especially in 
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Table 1 Demographic baseline characteristics and treatment (mean ± SD)
Women (n = 149) Men (n = 204) p-value
Age (years) 65.6 ± 16.6 63.6 ± 13.8 n.s.
Weight (kg) 69.6 ± 18.4 81.3 ± 15.4 0.001
ASA class 2.4 ± 0.7 2.5 ± 0.6 n.s.
Heart failure NYHA ≥ 1 [n (%)] 35 (23.5 %) 32 (15.7 %) n.s.
Current beta-blocker therapy [n (%)] 50 (33.6 %) 61 (29.9 %) n.s.
Heart failure NYHA ≥ 1 and beta-blocker therapy 
[n (%)]
18 (12.1 %) 18 (8.8 %) n.s.
Score by Canadian Cardiovascular Society 0.2 ± 0.5 0.1 ± 0.4 n.s.
Volume load with crystalloids (ml) 481 ± 293 493 ± 287 n.s.
Baseline MAP (mmHg) 81.8 ± 12.8 82.2 ± 14.5 n.s.
MAP after decrease (mmHg); reference 62.4 ± 8.9 63.8 ± 11.4 n.s.
Dosage Akrinor® (cafedrine mg/kg)a 1.3 ± 1.0 1.2 ± 1.0 n.s.
ASA American Society of Anesthesiologists, NYHA New York Heart Association, MAP mean arterial pressure
aCafedrine:theodrenaline fixed milligram ratio = 20:1
Table 2 Gender-related pharmacodynamic effects of cafedrine/theodrenaline (mean ± SD)
Women (n = 149) Men (n = 204) p-value
10 % MAP increase (min) 7.2 ± 4.6 8.6 ± 6.3 0.018
Time to maximum MAP effect (min) 17.0 ± 9.1 17.7 ± 9.0 n.s.
Table 3 Conversion table for cafedrine/theodrenaline dosages into ml of standard dilutions
Akrinor® ampoules 1 1/2 1/4
Cafedrine (mg) 200 100 50
Theodrenaline (mg) 10 5 2.5
Akrinor® solution undiluted (ml) 2 1 0.5
Akrinor® 1 ampoule diluted to 10 ml (ml) 10 5 2.5
Mean study dosage Akrinor® per 75 kg BW (amp)a 0.48
aStudy mean dosage used was 1.3 ± 1.0 mg/kg (Cafedrine), 64 ± 50 µg/kg (Theodrenaline)
elderly patients [4, 28] and during more 
extensive surgical interventions [20]. A 
pilot study [13] suggested that male gen-
der, heart failure and beta-blocking agents 
are factors that negatively influence the 
effectiveness of cafedrine/theodrenaline. 
Here we performed more in-depth analy-
ses (Kaplan–Meier analyses) using an in-
dependent patient population to further 
elucidate the influences. We aimed to in-
clude a broad range of patients that had a 
≥ 5 % blood pressure drop to represent a 
real-life population, regardless of under-
lying conditions. The range of the drop in 
blood pressure may vary in relation to the 
underlying disease; this study focuses on 
the therapy of the hypotensive states.
Blood pressure restoration with 
pure alpha- or beta-adrenergic 
agents vs. cafedrine/theodrenaline
Due to the limited half-life, bolus admin-
istration of catecholamines has only a 
short-term circulatory effect [7]. More-
over, bolus injection of pure alpha-ago-
nists cause an undesirable direct increase 
in peripheral resistance, resulting in ad-
ditional energy-consuming wall tension 
in the myocardium [5] and bradycardia, 
necessitating additional pharmacologic 
treatment with atropine [7]. Alternative-
ly, pure beta-mimetic drugs induce a de-
layed increase in blood pressure, due to 
initial vascular beta2-stimulation and the 
dependency on vascular filling; as a con-
sequence, undesirable increases in heart 
rate are observed [18].
Here we show that the administration 
of cafedrine/theodrenaline significantly 
increased MAP in both genders without 
affecting the heart rate in a clinically sig-
nificant manner. These observations are 
in line with experimental investigations 
[9, 11] and small clinical studies [13, 24].
Affecting the effectiveness: 
gender, beta-blocking 
agents and heart failure
The time to 10 % MAP increase in this 
cohort was longer in men and in patients 
who had previously received beta-block-
ing agents. The more rapid increase in 
MAP in women may be attributable to 
the lower cafedrine/theodrenaline ED50 
[13] and/or the higher intravascular flu-
id volume is observed in women [23] due 
to the higher level of endogenous oestro-
gen and resulting increase in preload. The 
downregulation of beta-receptors in old-
er men [8] and oestrogen receptor-de-
pendent effect that protects women from 
left ventricular hypertrophy and conges-
tive heart failure [2] might represent con-
tributing factors as well. Although poten-
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Fig. 3 8 Kaplan–Meier analysis of the time to 10 % mean arterial pressure (MAP) increase in male 
(dotted line) and female (solid line) patients after cafedrine/theodrenaline injection at time point 0 
(p = 0.018, log-rank test)
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Fig. 4 8 Kaplan–Meier analysis of the time to highest mean arterial pressure (MAP) after cafedrine/
theodrenaline injection at time point 0 in patients with heart failure (NYHA ≥ 1, dotted line) and 
healthy patients (solid line) (p = 0.007, log-rank test). Cases not reaching a MAP increase of 20 % with-
in 30 min were censored
 
tially not relevant under day-to-day cir-
cumstances, during acute sympathicoly-
sis-dependent hypotension these factors 
[2, 8] could have a clinical effect and at 
least partially explain the gender-related 
difference in the time to effect after cafe-
drine/theodrenaline administration. The 
effect of concomitant beta-blocker thera-
py on the effectiveness of cafedrine/theo-
drenaline is not surprising, given the pre-
dominantly beta-mimetic effects of this 
drug combination [24, 25] Patients with 
heart failure required longer to reach the 
maximum MAP and required higher dos-
es of cafedrine/theodrenaline. Apparently 
patients with heart failure are not able to 
respond to stimulation by alpha- and be-
ta-adrenergic agents [13].
Limitations
This study has a number of limitations. 
The association between heart failure and 
the use of beta-blockers and the influence 
of health status and gender on the type 
of anaesthesia (general vs. regional) ad-
ministered may have introduced sourc-
es of selection bias, especially in patients 
with heart failure receiving beta-blockers. 
Larger prospective and controlled stud-
ies with a more strictly defined and strati-
fied patient populations are certainly war-
ranted.
Conclusion for clinical practice
 5 Cafedrine/theodrenaline results in a 
rapid haemodynamic effect on blood 
pressure without affecting heart rate 
to a clinically significant extent.
 5 Male gender, heart failure and the 
previous administration of beta-
blocking agents negatively affect the 
effectiveness of cafedrine/theodren-
aline.
 5 Prospective studies to characterise 
the effect of cafedrine/theodrenaline 
in defined patient populations are 
warranted.
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Fig. 5 8 Kaplan–Meier analysis of the time to 10 % mean arterial pressure (MAP) increase after cafe-
drine/theodrenaline injection at time point 0 in patients with (dotted line) and without (solid line) cur-
rent beta-blocker therapy (p = 0.008, log-rank test)
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Situation ländlicher Kliniken ist 
kritisch
Rund 44% aller ländlichen Krankenhäuser 
schreiben Verluste. Nur etwas mehr als ein 
Drittel erzielt positive Ergebnisse. Gut 40% 
der Kliniken erwarten für 2015 eine weitere 
Verschlechterung ihrer Lage. Das ist das Er-
gebnis einer Studie der BDO AG Wirtschafts-
prüfungsgesellschaft in Zusammenarbeit 
mit dem Deutschen Krankenhausinstitut 
(DKI). Anhaltender Kostendruck, Investi-
tionsstau, Fachkräftemangel und demografi-
scher Wandel verursachen auf dem Land 
weit größere Probleme als in Großstädten 
und Ballungsgebieten. Die Sicherung der 
Wirtschaftlichkeit, der Erhalt der Investi-
tionsfähigkeit und der sich verschärfende 
Fachkräftemangel sind derzeit die größten 
Herausforderungen für die ländlichen Kran-
kenhäuser. Hier sind innovative Konzepte 
und ein tiefgreifender Strukturwandel ge-
fragt. Dabei wächst die Bedeutung gerade 
der ländlichen Kliniken derzeit signifikant, 
denn Defizite in der ambulanten ärztlichen 
Versorgung sorgen für steigende Patien-
tenzahlen in den Notaufnahmen. Wichtig 
in der aktuellen Lage sind den befragten 
Krankenhäusern gesundheitspolitische 
Strukturmaßnahmen für den ländlichen 
Raum, wie etwa der Ausbau von Kliniken zu 
regionalen Gesundheitszentren, die Versor-
gungsprozesse sektorübergreifend steuern 
und integrieren. Den höchsten Anteil länd-
licher Krankenhäuser haben die östlichen 
Bundesländer (Mecklenburg-Vorpommern 
97%, Thüringen 90%, Brandenburg 86%, 
Sachsen-Anhalt 76%, Sachsen 96%). Auch 
in Schleswig-Holstein stellen sie mit 69% 
die Mehrzahl der Kliniken, ebenso in Nieder-
sachsen mit 54%. Gerade dort stehen die 
ländlichen Krankenhäuser aktuell vor den 
größten Schwierigkeiten.
Quelle: BDO, www.bdo.de
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